Biotech

All Articles

Zephyrm seeks Hong Kong IPO to fund stage 3 cell treatment trials

.Zephyrm Bioscience is actually gusting towards the Hong Kong stock exchange, submitting (PDF) for a...

Frazier Lifestyle Sciences gathers $630M for tiny, mid-cap biotechs

.Frazier Everyday life Sciences has sourced a better $630 million for its fund concentrated on littl...

GigaGen amasses as much as $135M BARDA dollars to beat botulism

.Antitoxin aficionado GigaGen, a subsidiary of Spanish biopharma Grifols, is actually ramping up its...

GPCR agency Septerna files for IPO on toughness of preclinical records

.Septerna will figure out just how a biotech without "any type of meaningful professional records" f...

Kurma closes initially $154M haul for most significant biotech fund yet

.International VC firm Kurma Allies has actually introduced its own most recent biotech fund, along ...

Prothena markets one exec while one more keeps-- Chutes &amp Ladders

.Welcome to today's Chutes &amp Ladders, our summary of significant management hirings, shootings an...

Editas exploit Tip Cas9 licensing civil liberties for $57M

.Versus the background of a Cas9 license fight that rejects to pass away, Editas Medication is actua...

Ultragenyx adjusts genetics therapy application to dial up efficacy

.A minority of patients taking Ultragenyx Pharmaceutical's Wilson ailment gene treatment UX701 have ...

Biopharma cutback cost maintains in Q3: Fierce Biotech evaluation

.As summertime warmth counts on cool down winds, really hopes that this year would bring wide-spread...

J &amp J falls phase 2 dengue applicant in most recent change from injections

.Johnson &amp Johnson's deprioritization of its own infectious disease pipe has professed another vi...